News

Citric Acid CQDs Shown to Protect Dopaminergic Neurons in Models

Nanomaterials with potent antioxidant properties called carbon quantum dots prevented Parkinson’s disease-related neurodegeneration in nerve cells and a worm model, a study reported. These antioxidants, especially those derived from citric acid — a common and nontoxic biochemical — may represent a new treatment approach for Parkinson’s and other neurodegenerative diseases,…

Pedaling for Parkinson’s Viewed Favorably by Patients in Study

People with Parkinson’s disease reported enjoying and benefiting physically and emotionally from a community cycling program — Pedaling for Parkinson’s (PFP) — viewing it favorably in a survey regardless of their age or disease symptoms and severity, a study of patients at five PFP sites reported. The aerobic program’s cost, access…

Koneksa Wins MJFF Grant to Investigate Digital Biomarkers

Koneksa has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to investigate the potential of digital biomarkers to evaluate and predict disease progression in people with Parkinson’s disease. Digital biomarkers have the potential to aid in diagnosing Parkinson’s and allowing patients…

Trial Failure of Antibody Targeting Alpha-synuclein Detailed

Treatment with prasinezumab, a monoclonal antibody designed to break up toxic alpha-synuclein aggregates, failed to slow the progression of Parkinson’s disease in a Phase 2 clinical trial. “In this placebo-controlled trial, treatment with prasinezumab, a humanized monoclonal antibody targeting aggregated [alpha]-synuclein, had no meaningful effect on global clinical or…

Nanobody Has Potential to Combat Alpha-synuclein Clumps

A miniature antibody-like molecule called a nanobody effectively broke up toxic alpha-synuclein aggregates that are characteristic of Parkinson’s disease, and prevented the spread of these aggregates in the brains of mice in a disease model. The novel construct was described in the journal Nature Communications, in the study, “…

Kynmobi Does Not Significantly Alter Heartbeat, Study Finds

Treatment with Kynmobi (apomorphine hydrochloride), an approved under-the-tongue therapy for “off” episodes in Parkinson’s disease, does not substantially alter heartbeat dynamics at approved doses, according to new clinical trial data. The study, “A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s…

Researchers Design New Approach to Help Medications Enter the Brain

Researchers have developed a new method of temporarily opening the selective blood-brain barrier (BBB) to allow therapeutic molecules greater access to the brain. Difficulties in developing molecules that can cross this barrier have long hindered the development of treatments for neurological diseases, like Parkinson’s disease. The technique could now…